title: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
abstract: Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin. Rasburicase is a new recombinant form of urate oxidase available for clinical evaluation. This multicenter randomized trial compared allopurinol to rasburicase in pediatric patients with leukemia or lymphoma at high risk for tumor lysis. Patients received the assigned uric acid-lowering agent for 5 to 7 days during induction chemotherapy. The primary efficacy end point was to compare the area under the serial plasma uric acid concentration curves during the first 96 hours of therapy (AUC(0-96)). Fifty-two patients were randomized at 6 sites. In an intent-to-treat analysis, the mean uric acid AUC(0-96) was 128 +/- 70 mg/dL.hour for the rasburicase group and 329 +/- 129 mg/dL.hour for the allopurinol group (P <.0001). The rasburicase versus allopurinol group experienced a 2.6-fold (95% CI: 2.0-3.4) less exposure to uric acid. Four hours after the first dose, patients randomized to rasburicase compared to allopurinol achieved an 86% versus 12% reduction (P <.0001) of initial plasma uric acid levels. No antirasburicase antibodies were detected at day 14. This randomized study demonstrated more rapid control and lower levels of plasma uric acid in patients at high risk for tumor lysis who received rasburicase compared to allopurinol. For pediatric patients with advanced stage lymphoma or high tumor burden leukemia, rasburicase is a safe and effective alternative to allopurinol during initial chemotherapy.
authors.affiliation: Department of Pediatric Hematology/Oncology at North Texas Hospital for Children at Medical City, Dallas, TX, USA.
authors.forename: S C
authors.initials: SC
authors.lastname: Goldman
authors.forename: J S
authors.initials: JS
authors.lastname: Holcenberg
authors.forename: J Z
authors.initials: JZ
authors.lastname: Finklestein
authors.forename: R
authors.initials: R
authors.lastname: Hutchinson
authors.forename: S
authors.initials: S
authors.lastname: Kreissman
authors.forename: F L
authors.initials: FL
authors.lastname: Johnson
authors.forename: C
authors.initials: C
authors.lastname: Tou
authors.forename: E
authors.initials: E
authors.lastname: Harvey
authors.forename: E
authors.initials: E
authors.lastname: Morris
authors.forename: M S
authors.initials: MS
authors.lastname: Cairo
mesh_terms: D000293:Adolescent; D000493:Allopurinol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D015507:Drugs, Investigational; D005260:Female; D006801:Humans; D007223:Infant; D007668:Kidney / Q000503:physiopathology; D007700:Kinetics; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008223:Lymphoma / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000209:etiology; D012307:Risk Factors; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000517:prevention & control*; D014503:Urate Oxidase / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood*
chemical_list: D015507:Drugs, Investigational; D011994:Recombinant Proteins; D014527:Uric Acid; D000493:Allopurinol; D003404:Creatinine; D014503:Urate Oxidase